Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant

McMaster University

$168,663.00

Optimizing the balance between Antithrombotic Efficacy and Bleeding Risk of Acetylsalicylic Acid in Patients with Acute Coronary Syndromes

EF 2008-09

Résumé
Aspirin is a single most widely used treatment for the prevention of heart attack and stroke. It works by blocking the ability of platelets ("sticky cells" in the blood ) to form blood clots. Studies to date have been interpreted to indicated that low doses of aspirin are no less effective than higher doses for blocking platelets and for preventing heart attack and stroke. We have evidence that challenges the notion that low dose aspirin optimally inhibits platelets and that its as effective as high dose aspirin for preventing the clotting of the blood. Thus, we and others have shown that (1) about one-third of patients treated with aspirin are "resistant" to its effect s (i.e. they do not achieve the expected benefits fro preventing heart attack and stroke); and (2) higher doses of aspirin appear to overcome the lack of response to aspirin. We also have evidence that (3) higher doses of aspirin cause more bleeding, which implies that they are more effective than low doses to "thin" the blood. How can we explain that higher doses of aspirin can overcome the problem of aspirin resistance and thin the blood more effectively than low doses but do not reduce heart attack and stroke? This issue is the focus of our study. We will measure the effect of aspirin on concentrations of two biochemical markers (thromboxane and prostaclyclin) in the urine. We hypothesize that the balance between these two markers accurately predicts the risk of heart attack and stroke in patients treated with aspirin and that adjustment of aspirin dose according to the levels of these markers will improve the effectiveness and safety of aspirin. The results of our study could enable physicians to individualize aspirin treatment, thereby maximizing its benefits and minimizing the risk of bleeding. Our study findings could also have implications for the development of new antiplatelet treatments by identifying targets for new drugs to reduce the risk of heart attack and stroke.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
179597
Name
Eikelboom John W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Cardiovascular System - B: Heart and Circulation
Projecttitle
Optimizing the balance between Antithrombotic Efficacy and Bleeding Risk of Acetylsalicylic Acid in Patients with Acute Coronary Syndromes
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$168,663
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Aspirin; Bleeding; Prostacyclin; Thrombosis; Thromboxane
Abstract
Aspirin is a single most widely used treatment for the prevention of heart attack and stroke. It works by blocking the ability of platelets ("sticky cells" in the blood ) to form blood clots. Studies to date have been interpreted to indicated that low doses of aspirin are no less effective than higher doses for blocking platelets and for preventing heart attack and stroke. We have evidence that challenges the notion that low dose aspirin optimally inhibits platelets and that its as effective as high dose aspirin for preventing the clotting of the blood. Thus, we and others have shown that (1) about one-third of patients treated with aspirin are "resistant" to its effect s (i.e. they do not achieve the expected benefits fro preventing heart attack and stroke); and (2) higher doses of aspirin appear to overcome the lack of response to aspirin. We also have evidence that (3) higher doses of aspirin cause more bleeding, which implies that they are more effective than low doses to "thin" the blood. How can we explain that higher doses of aspirin can overcome the problem of aspirin resistance and thin the blood more effectively than low doses but do not reduce heart attack and stroke? This issue is the focus of our study. We will measure the effect of aspirin on concentrations of two biochemical markers (thromboxane and prostaclyclin) in the urine. We hypothesize that the balance between these two markers accurately predicts the risk of heart attack and stroke in patients treated with aspirin and that adjustment of aspirin dose according to the levels of these markers will improve the effectiveness and safety of aspirin. The results of our study could enable physicians to individualize aspirin treatment, thereby maximizing its benefits and minimizing the risk of bleeding. Our study findings could also have implications for the development of new antiplatelet treatments by identifying targets for new drugs to reduce the risk of heart attack and stroke.
Competitiondate
200903
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Eikelboom, John W
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $168,663~ $0~